Skip to main content

Table 3 Promoter hypermethylation in various phases of treatment in NSGCT

From: Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

Gene

Phase1

    

p-value3

 

P/M1 (N = 22)

C1 (N = 32)

C2/C3 (N = 16)

P/M1 vs C1

P/M1 vs C2/C3

APC

2 (9.1)

8 (25)

7 (43.8)

0.25

0.03

BRCA12

4 (18.2)

12 (37.5)

2 (13.3)

0.22

1.0

HIC12

3 (13.6)

11 (34.4)

8 (53.5)

0.17

0.09

MGMT

0

11 (34.4)

3 (18.8)

0.0034

RARB

0

4 (12.5)

0

0.144

RASSF1A

5 (22.7)

10 (31.3)

10 (62.5)

0.72

0.09

  1. 1 See Table 1 for definition of phase 2 Only 15 tumors studied in C2/C3 phase 3 Adjusted for sensitive/resistant status 4 Model cannot be fit due to sparse data; Fisher's exact p-value given